Clinical Trial Detail

NCT ID NCT02619669
Title Neoadjuvant Run-In Study With TAK-228 (MLN0128) Followed by Letrozole/TAK-228 (MLN0128) in Women With High-Risk ER+/HER2- Breast Cancer
Recruitment Recruiting
Gender female
Phase Phase I
Variant Requirements yes
Sponsors Dartmouth-Hitchcock Medical Center
Indications

Her2-receptor negative breast cancer

Therapies

Sapanisertib

Letrozole

Age Groups: adult

Additional content available in CKB BOOST